hero image

A statement from Biogen on LEQEMBI™ pricing

January 6, 2023 Company Statements

Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBITM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety is available on Eisai’s website.

A separate news release from Eisai on LEQEMBI pricing is also available via their website.  Eisai is solely responsible for setting LEQEMBI’s price.

thumb
November 16, 2023
Biogen to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Cambridge, MA, - - Biogen.com announced today that Priya Sighal, M.D., M.P.H., Head of Development, will participate in the 6th Annual Evercore ISI HealthCONx Conference. The webcast will be live on Tuesday, Nov 28, 2023, at 9:10 a.m. ET. To access the live webcast, please visit the Investors

thumb
November 8, 2023
Biogen Reports Third Quarter 2023 Results